News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Chris Williams: New analysis of CD3/CD8 TILs in QUASAR trial
Photo of Chris Williams taken from Chris Williams/X
Aug 3, 2024, 00:15

Chris Williams: New analysis of CD3/CD8 TILs in QUASAR trial

Chris Williams, Medical oncologist at Leeds Hospitals, shared on X:

“Adjuvant chemotherapy decisions are complex in stage 2 colon cancer.

New analysis of CD3/CD8 TILs in QUASAR trial.

1st in early CRC RCT (colorectal cancer randomized controlled trial)

Stronger prognostic effect than any routinely measured stage 2 ‘high risk’ feature

High vs low CD3 Score = 3x 5 years recurrence risk.”

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial

Authors: Christopher J.M. Williams, Richard Gray, Robert K. Hills, Michael Shires, Liping Zhang, Zuo Zhao, Tracie Gardner, Nancy Sapanara, Xiao-Meng Xu, Isaac Bai, Dongyao Yan, Andrea Muranyi, Sarah Dance, Faranak Aghaei, Gemma Hemmings, Michael Hale, Uday Kurkure, Christoph Guetter, Susan D. Richman, Gordon Hutchins, Jenny F. Seligmann, Nicholas P. West, Shalini Singh, Kandavel Shanmugam and Philip Quirke.

Chris Williams: New analysis of CD3/CD8 TILs in QUASAR trial

Source: Chris Williams/X

adjuvant chemotherapy Andrea Muranyi cancer CD3/CD8 TILs Chris Williams Christoph Guetter Christopher J.M. Williams Colon cancer colorectal cancer CRC Dongyao Yan Faranak Aghaei Gemma Hemmings Gordon Hutchins Isaac Bai Jenny F. Seligmann Kandavel Shanmugam Leeds Hospitals Liping Zhang Michael Hale Michael Shires Nancy Sapanara Nicholas P. West OncoDaily Oncology Philip Quirke QUASAR trial randomized controlled trial RCT Richard Gray Robert K. Hills Sarah Dance Shalini Singh Susan D. Richman Tracie Gardner Uday Kurkure Xiao-Meng Xu Zuo Zhao
Special Coverage
Career
Dec 21, 2024, 07:45
OncoInfluencers to Follow on Social Media: Dr. Liang Cheng
Insight
Dec 21, 2024, 07:31
Update on U.S. regulatory review of subcutaneous amivantamab for EGFR + lung cancer
Science
Dec 21, 2024, 07:05
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Blog
Dec 21, 2024, 05:54
LCC in Spanish: LALCA 2024 Highlights
Blog
Dec 21, 2024, 05:50
The Opportunities Are Endless: CU Cancer Center leader Enrique Soto Pérez de Celis signs key international agreement
Insight
Dec 21, 2024, 05:42
Raffaella Casolino: How to integrate cancer into crisis?
Insight
Dec 21, 2024, 05:01
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Blog
Dec 21, 2024, 05:01
Omolola Salako: A year ago, Pearl Oncology Specialist Hospital became a 24-hour, 10-bed cancer center
Science
Dec 21, 2024, 04:57
Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Blog
Dec 21, 2024, 04:55
Milan Mishkovikj: The Patient at the Center - Value-Based Healthcare in Oncology
Insight
Dec 21, 2024, 04:52
Do national cancer control plans address care and research for children and AYAs - SIOP
Insight
Dec 21, 2024, 04:36
A holistic global strategy for incorporating cancer care into crisis response initiatives - The Institute of Cancer and Crisis